Beckley and atai leadership unpack Phase 2b results for intranasal 5-MeO-DMT, focusing on adverse events and trial dosing comparisons

Intranasal 5-MeO-DMT Phase 2b data for treatment-resistant depression is discussed by Beckley Psytech and atai Life Sciences leadership in a call followed by this update. The executives frame topline results as exceeding expectations, while the scientific leadership shares trial color on baseline participant characteristics, responder and remission rates, and a more detailed adverse event profile across three doses. The update also compares Beckley’s trial context to GH’s, emphasizing baseline MADRS severity and depressive episode duration to help explain differences in symptom reduction at the day 8 blinded endpoint (including how the dosing approach and patient differences affect interpretability).